IGF1 and prostate cancer: This is the first study, to our knowledge, showing that the addition of exogenous IGF-1 to prostate cancer cells results in a significant increase in invasive potential, and that these effects are reduced by inhibiting IGF-1R, the MAPK pathway or the PI3-K pathway.